Scope

Nonagen Therapeutics is an early-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in oncologic conditions leveraging molecular oncology and immune-oncology pathways. We are advancing our pipeline to address a number of diseases across therapeutic categories including oncology, ophthalmological diseases with abnormal angiogenesis, rheumatoid arthritis, psoriasis, angioma, endometriosis, and Kaposi sarcoma.